Sökning: "Npm1"

Visar resultat 6 - 10 av 16 avhandlingar innehållade ordet Npm1.

  1. 6. Measurable residual disease and clonal evolution in acute myeloid leukemia with focus on NPM1-mutations

    Författare :Louise Pettersson; Lund Patologi; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; AML; MRD; Measurable residual disease; NPM1; NPM1-mutation; NPM1 type A mutation; clonal evolution; clonal patterns; subclones; genetic evolution; qPCR; RQ-PCR; ddPCR; deep seq; deep sequencing; NGS; RT-qPCR; old; elderly; MFC; flow cytometry;

    Sammanfattning : Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with mutations in the NPM1 gene occurring in almost one third of all cases. The ability to detect residual leukemia below the resolution of conventional microscopy is crucial for evaluation of relapse risk after therapy. LÄS MER

  3. 7. Studies of anemia in the myelodysplastic syndromes

    Författare :Martin Jädersten; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :Myelodysplasia; growth factors; Cox regression; delayed entry; left truncation; mortality; international prognostic scoring system; IPSS; who-classification based prognostic scoring system; WPSS; thalidomide analogue; IMiD; hematopoietic stem cell; adhesion; stroma; matrix; osteonectin; matricellular protein; NPM1; immunohistochemistry.;

    Sammanfattning : Background: The myelodysplastic syndromes (MDS) constitute a heterogeneous group of malignant bone marrow disorders, characterized by chronic anemia and increased risk of transformation to acute myeloid leukemia (AML). The first line therapy of anemia in MDS is erythropoietin (EPO) with or without granulocyte colony-stimulating factor (G-CSF). LÄS MER

  4. 8. Molecular subclassification, stem cell markers and growth regulatory pathways in gliomas

    Författare :Karl Holmberg Olausson; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : Glioblastoma is the most common and aggressive primary brain tumor in adults. Median survival is no more than 15 months, even with combined treatment regimens. The lack of accurate pre-clinical model systems has limited the development of new treatment options for this deadly disease. LÄS MER

  5. 9. Functional investigation of prognostic biomarkers and therapeutic targets in glioma brain tumors

    Författare :Kaveh M Goudarzi; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : Gliomas are known to be the most prevalent primary tumors of the central nervous system, of which glioblastoma is the most aggressive type with a median survival less than 2 years and no available cure. Studies in this thesis investigated the significance of two potentially important proteins in glioma biology, the transcription factor PROX1 and the histone chaperone NPM1, and the interplay of the therapeutic targets p53 and mTOR. LÄS MER

  7. 10. Prognostic markers in acute myeloid leukemia : A candidate gene approach

    Författare :Ingrid Jakobsen; Kourosh Lotfi; Henrik Gréen; Anna Fyrberg; Christian Thiede; Linköpings universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES;

    Sammanfattning : The standard treatment of acute myeloid leukemia (AML) consists of induction chemotherapy, most commonly daunorubicin together with the nucleoside analogue cytarabine (Ara-C), followed by consolidation chemotherapy and in selected cases allogenic stem cell transplantation (allo-SCT). Despite a high initial response rate, a considerable proportion of all AML cases eventually suffer from relapse and the five-year overall survival rate in patients >60 years is only around 15%. LÄS MER